Proactive Investors - Run By Investors For Investors

Rhinomed Limited to update on first stage of global pharmacy distribution

Rhinomed Limited to update on first stage of global pharmacy distribution

Rhinomed Limited (ASX:RNO) has been granted an ASX trading halt in relation to the first stage in global pharmacy distribution.

The halt will last until the earlier of the announcement being made or the start of trade on Friday, 21st August 2015.

In the June 2015 Quarter, the company reported receipts from customers of $192,000, an increase of $33,000 from the previous quarter due to growing demand for its Turbine sports breathing device.

Sales in FY2016 are expected to increase due to expanded global distribution of Turbine. It has also received early demand for its Mute snoring and sleep technology.

Rhinomed had $1.37 million in cash as at 30th June 2015.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full RNO profile View Profile

Rhinomed Ltd Timeline

Newswire
September 15 2015

Related Articles

antibodies
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences
1557403923_iron.jpg
May 09 2019
Here we take a look under the hood of Shield Therapeutics
woman's face
Tue
Here we take a closer look at SkinBioTherapeutics, the life sciences group that is using bacteria to improve people’s skin
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use